Get the Stockscreener App
250.88
0.32%
0.79
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $250.88, with a volume of 635.90K.
It is up +0.32% in the last 24 hours and down -0.32% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$250.09
Open:
$250.25
24h Volume:
635.90K
Relative Volume:
0.64
Market Cap:
$37.05B
Revenue:
$5.02B
Net Income/Loss:
$1.31B
P/E Ratio:
28.16
EPS:
8.91
Net Cash Flow:
$1.56B
1W Performance:
-0.19%
1M Performance:
-0.32%
6M Performance:
+8.98%
1Y Performance:
+18.19%
1-Day Range:
$249.60
$253.73
1-Week Range:
$248.20
$254.03
52-Week Range:
$179.42
$263.05
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
250.88 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
ISRG
Intuitive Surgical Inc
|
509.49 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
168.59 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
84.77 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
217.95 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Is the ResMed share price still cheap? What the numbers say - The Motley Fool Australia
ResMed’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Bi Level Automatic Ventilator Market Is Booming Worldwide 2025-2032 | ResMed Inc., Philips Healthcare, Medtronic Plc - openPR.com
ResMed Stock: Is RMD Outperforming the Healthcare Sector? - MSN
ResMed Inc. (RMD) Investor Outlook: Analyzing Growth Potential Amidst a 6% Upside - DirectorsTalk Interviews
Resmed CEO Michael Farrell sells shares worth $2.01 million By Investing.com - Investing.com South Africa
ResMed: A Mixed Bag for Investors Amid Rising Competition - The Globe and Mail
Resmed CEO Michael Farrell sells shares worth $2.01 million - Investing.com
ResMed CEO Sells Shares Worth $2 Million - MarketScreener
ResMed Inc Reports Change in Beneficial Ownership - TipRanks
ResMed: A Sleeping Giant Hiding In Plain Sight (NYSE:RMD) - Seeking Alpha
Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell? - MSN
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed director Peter Farrell sells $494,640 in stock By Investing.com - Investing.com Nigeria
ResMed director Peter Farrell sells $494,640 in stock - Investing.com Australia
ResMed Inc Director Proposes Sale of Common Shares - TipRanks
Successful Exits - University College Dublin
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells Shares - marketscreener.com
Resmed Inc Reports Decrease in CDI Issuance for May 2025 - TipRanks
ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan - TipRanks
ResMed Inc. Officer Files Notice for Proposed Sale of Securities - TipRanks
ResMed’s global general counsel Michael Rider sells $9,994 in shares By Investing.com - Investing.com Nigeria
ResMed’s global general counsel Michael Rider sells $9,994 in shares - Investing.com Australia
Dental Sleep Medicine Market Projected to Witness Massive GrowthResMed Inc., SomnoMed Limited - openPR.com
Citi raises ResMed stock price target to AUD45 citing strong EPS growth - Investing.com Nigeria
Here's why I invested MORE money in ResMed shares last week - MSN
There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price - simplywall.st
Sleep Apnea Oral Appliances MarketGlobal Forecast to 2030 with SomnoMed, Resmed, ProSomnus, DynaFlex, Vivos Therapeutics, and OpenAirway Leading - Yahoo Finance
ResMed Inc. Files Conflict Minerals Disclosure Report for 2024 - TipRanks
Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape - GlobeNewswire Inc.
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $891,285 in stock By Investing.com - Investing.com South Africa
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Chase Coleman, John Paulson, Polus Capital Management, VFC Corp (VFC), ResMed Inc (RMD), and More - Insider Monkey
ResMed CFO Brett Sandercock sells $891,285 in stock - Investing.com Australia
Equities Analysts Issue Forecasts for ResMed Q1 Earnings - Defense World
ResMed’s SWOT analysis: sleep tech giant faces growth challenges, new markets - Investing.com
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Are Wall Street Analysts Bullish on ResMed Stock? - Inkl
Are Wall Street Analysts Bullish On ResMed Stock? - Barchart.com
Is it Worth Retaining ResMed Stock in Your Portfolio Now? - Nasdaq
Insider Sell: Witte De Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
Why Kogan, Monash IVF, OFX, and ResMed shares are falling today - MSN
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Resmed Inc Stock (RMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chief Executive Officer |
Jun 09 '25 |
Sale |
251.21 |
8,009 |
2,011,910 |
455,503 |
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):